Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Sebastian

Showing results (151-160 of 183) with videos related to

Pageof 19
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 9, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) ImmunotherapyMarcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.
Lung Cancer (Amsterdam, Netherlands)|February 21, 2021
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)Martin Sebastian, Wilfried E E Eberhardt, Petra Hoffknecht, et al.
Oncotarget|April 15, 2015
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variabilityMatthias Scheffler, Anne Schultheis, Cristina Teixido, et al.
Nature Medicine|May 31, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trialMartin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
Lung Cancer (Amsterdam, Netherlands)|May 13, 2021
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and CanadaDidier Debieuvre, Rosalyn A Juergens, Bernard Asselain, et al.
Advances in Therapy|January 18, 2023
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion MutationsChristos Chouaid, Lise Bosquet, Nicolas Girard, et al.
The Lancet Regional Health. Europe|November 30, 2023
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysisAnika Kästner, Anna Kron, Neeltje van den Berg, et al.
Neurological Research and Practice|April 3, 2024
Status epilepticus in patients with brain tumors and metastases: A multicenter cohort study of 208 patients and literature reviewJohanna K Rickel, Daria Zeeb, Susanne Knake, et al.
Nature Medicine|June 19, 2026
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trialMartin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
Cancer Immunology, Immunotherapy : CII|February 17, 2019
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancerMartin Sebastian, Andreas Schröder, Birgit Scheel, et al.
Pageof 19

Showing results (151-160 of 183) with videos related to

Sort By:
Pageof 19
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 9, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) ImmunotherapyMarcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.
Lung Cancer (Amsterdam, Netherlands)|February 21, 2021
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)Martin Sebastian, Wilfried E E Eberhardt, Petra Hoffknecht, et al.
Oncotarget|April 15, 2015
ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variabilityMatthias Scheffler, Anne Schultheis, Cristina Teixido, et al.
Nature Medicine|May 31, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trialMartin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
Lung Cancer (Amsterdam, Netherlands)|May 13, 2021
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and CanadaDidier Debieuvre, Rosalyn A Juergens, Bernard Asselain, et al.
Advances in Therapy|January 18, 2023
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion MutationsChristos Chouaid, Lise Bosquet, Nicolas Girard, et al.
The Lancet Regional Health. Europe|November 30, 2023
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysisAnika Kästner, Anna Kron, Neeltje van den Berg, et al.
Neurological Research and Practice|April 3, 2024
Status epilepticus in patients with brain tumors and metastases: A multicenter cohort study of 208 patients and literature reviewJohanna K Rickel, Daria Zeeb, Susanne Knake, et al.
Nature Medicine|June 19, 2026
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trialMartin Wermke, Sebastian Ochsenreither, Dirk Jaeger, et al.
Cancer Immunology, Immunotherapy : CII|February 17, 2019
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancerMartin Sebastian, Andreas Schröder, Birgit Scheel, et al.
Pageof 19